title: Significance of thymosin β4 and implication of PINCH-1-ILK-α-parvin (PIP) complex in human dilated cardiomyopathy.
abstract: Myocardial remodeling is a major contributor in the development of heart failure (HF) after myocardial infarction (MI). Integrin-linked kinase (ILK), LIM-only adaptor PINCH-1, and α-parvin are essential components of focal adhesions (FAs), which are highly expressed in the heart. ILK binds tightly to PINCH-1 and α-parvin, which regulates FA assembly and promotes cell survival via the activation of the kinase Akt. Mice lacking ILK, PINCH or α-parvin have been shown to develop severe defects in the heart, suggesting that these proteins play a critical role in heart function. Utilizing failing human heart tissues (dilated cardiomyopathy, DCM), we found a 2.27-fold (p<0.001) enhanced expression of PINCH, 4 fold for α-parvin, and 10.5 fold (p<0.001) for ILK as compared to non-failing (NF) counterparts. No significant enhancements were found for the PINCH isoform PINCH-2 and parvin isoform β-parvin. Using a co-immunoprecipitation method, we also found that the PINCH-1-ILK-α-parvin (PIP) complex and Akt activation were significantly up-regulated. These observations were further corroborated with the mouse myocardial infarction (MI) and transaortic constriction (TAC) model. Thymosin beta4 (Tβ4), an effective cell penetrating peptide for treating MI, was found to further enhance the level of PIP components and Akt activation, while substantially suppressing NF-κB activation and collagen expression--the hallmarks of cardiac fibrosis. In the presence of an Akt inhibitor, wortmannin, we show that Tβ4 had a decreased effect in protecting the heart from MI. These data suggest that the PIP complex and activation of Akt play critical roles in HF development. Tβ4 treatment likely improves cardiac function by enhancing PIP mediated Akt activation and suppressing NF-κB activation and collagen-mediated fibrosis. These data provide significant insight into the role of the PIP-Akt pathway and its regulation by Tβ4 treatment in post-MI.
authors.affiliation: Department of Stem Cell and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
authors.forename: Nikolai
authors.initials: N
authors.lastname: Sopko
authors.forename: Yilu
authors.initials: Y
authors.lastname: Qin
authors.forename: Amanda
authors.initials: A
authors.lastname: Finan
authors.forename: Alisher
authors.initials: A
authors.lastname: Dadabayev
authors.forename: Sravanthi
authors.initials: S
authors.lastname: Chigurupati
authors.forename: Jun
authors.initials: J
authors.lastname: Qin
authors.forename: Marc S
authors.initials: MS
authors.lastname: Penn
authors.forename: Sudhiranjan
authors.initials: S
authors.lastname: Gupta
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D002311:Cardiomyopathy, Dilated / Q000503:physiopathology*; D004268:DNA-Binding Proteins / Q000502:physiology*; D006801:Humans; D060588:LIM Domain Proteins; D008565:Membrane Proteins; D051379:Mice; D008840:Microfilament Proteins / Q000502:physiology*; D009203:Myocardial Infarction / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000502:physiology*; D013947:Thymosin / Q000502:physiology*; D000099201:Thymosin beta(4); D000099200:Scaffold Protein ILK
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D004268:DNA-Binding Proteins; D060588:LIM Domain Proteins; D008565:Membrane Proteins; D008840:Microfilament Proteins; D016328:NF-kappa B; D017346:Protein Serine-Threonine Kinases; D013947:Thymosin; D000099201:Thymosin beta(4); D000099200:Scaffold Protein ILK; C490232:Lims1 protein, mouse; C519774:Parva protein, mouse